Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 84

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 84
---
 management will devote substantial time to new compliance activities. •Following the completion of the Business Combination we may still require substantial additional funding to finance our operations, but adequate additional financing may not be available when we need it, on acceptable terms or at all. •There can be no assurance that the New Profusa Warrants and the New Profusa Common Stock that will be issued in connection with the Business Combination (including New Profusa Common Stock underlying the New Profusa Warrants) will be approved for listing on Nasdaq or, if approved, will continue to be so listed following the closing of the Business Combination, or that New Profusa will be able to comply with the continued listing standards of Nasdaq. •A market for New Profusa’s securities may not continue, which would adversely affect the liquidity and price of its securities. •If, following the Business Combination, securities or industry analysts do not publish or cease publishing research or reports about New Profusa, its business, or its market, or if they change their recommendations regarding New Profusa Common Stock adversely, then the price and trading volume of New Profusa Common Stock could decline. •The JOBS Act permits “emerging growth companies” like New Profusa to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies. •New Profusa is subject to business uncertainties and contractual restrictions while the Business Combination is pending. •NorthView’s and Profusa’s ability to consummate the Business Combination, and the operations of New Profusa following the Business Combination, may be materially adversely affected by the recent coronavirus (COVID -19) pandemic. 17 •If the net proceeds of NorthView’s IPO and the sale of the private placement warrants not being held in the trust account are insufficient, NorthView may not be able to complete the Business Combination. •The process of taking a company public by means of a business combination with a special purpose acquisition company (“SPAC”) is different from taking a company public through an underwritten offering and may create risks for our unaffiliated investors. Regulatory Risks •We are exposed to risks related to our international operations and failure to manage these risks may adversely affect our results of operations and financial condition. •We are subject to anti -corruption, anti -bribery, anti -moneylaundering and similar laws, and non -compliancewith such laws can subject us to criminal and/or civil liability and harm our business. •Import and Export Control Laws and Regulations •Our business may be subject